Thrivent Financial for Lutherans trimmed its holdings in shares of Enovis Corporation (NYSE:ENOV – Free Report) by 18.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 96,171 shares of the company’s stock after selling 21,327 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Enovis were worth $2,562,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in Enovis by 2.0% during the third quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock valued at $197,945,000 after acquiring an additional 125,460 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Enovis by 1.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock valued at $90,156,000 after acquiring an additional 51,201 shares during the period. Rubric Capital Management LP bought a new stake in Enovis during the third quarter valued at about $83,435,000. Paradigm Capital Management Inc. NY boosted its holdings in Enovis by 41.6% during the second quarter. Paradigm Capital Management Inc. NY now owns 1,113,300 shares of the company’s stock valued at $34,913,000 after acquiring an additional 326,900 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Enovis by 11.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 757,673 shares of the company’s stock valued at $20,086,000 after acquiring an additional 78,497 shares during the period. 98.45% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Enovis
In related news, insider Oliver Engert bought 1,000 shares of Enovis stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average price of $25.50 per share, for a total transaction of $25,500.00. Following the completion of the purchase, the insider owned 43,640 shares in the company, valued at approximately $1,112,820. This represents a 2.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have bought a total of 5,000 shares of company stock valued at $121,983 in the last three months. 2.90% of the stock is currently owned by company insiders.
Enovis Stock Down 0.1%
Enovis (NYSE:ENOV – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business had revenue of $589.15 million during the quarter, compared to analysts’ expectations of $572.02 million. During the same quarter last year, the company earned $0.81 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts forecast that Enovis Corporation will post 3.65 EPS for the current year.
Analyst Ratings Changes
A number of research firms have issued reports on ENOV. Weiss Ratings restated a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Enovis in a report on Friday. Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a report on Sunday, May 10th. Evercore restated an “outperform” rating and set a $36.00 price target on shares of Enovis in a report on Friday, May 8th. Finally, Zacks Research upgraded shares of Enovis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $44.50.
View Our Latest Stock Analysis on ENOV
About Enovis
Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.
The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.
Featured Articles
- Five stocks we like better than Enovis
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding ENOV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enovis Corporation (NYSE:ENOV – Free Report).
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
